Stratos Wealth Advisors LLC Purchases Shares of 5,565 CRISPR Therapeutics AG $CRSP

Key Points

• Stratos Wealth Advisors LLC acquired 5,565 shares of CRISPR Therapeutics AG, valued at approximately $271,000, in the second quarter.
• CRISPR's stock price opened at $73.97, with a market capitalization of $6.73 billion, and the company reported a quarterly revenue increase of 72.5% year-over-year.
• CEO Samarth Kulkarni sold 50,895 shares for approximately $3.46 million, reflecting a 16.68% decrease in his ownership stake in the company.

Stratos Wealth Advisors LLC purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,565 shares of the company's stock, valued at approximately $271,000.

A number of other large investors have also added to or reduced their stakes in CRSP. GAMMA Investing LLC raised its position in CRISPR Therapeutics by 8,146.2% during the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company's stock valued at $146,000 after purchasing an additional 4,236 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of CRISPR Therapeutics by 244.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 94,100 shares of the company's stock worth $3,202,000 after buying an additional 66,789 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of CRISPR Therapeutics by 55.7% in the first quarter. Janney Montgomery Scott LLC now owns 10,703 shares of the company's stock worth $364,000 after buying an additional 3,827 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in shares of CRISPR Therapeutics by 14.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock worth $1,334,000 after buying an additional 4,914 shares during the period. Finally, Tyche Wealth Partners LLC increased its holdings in shares of CRISPR Therapeutics by 10.2% in the first quarter. Tyche Wealth Partners LLC now owns 9,185 shares of the company's stock worth $313,000 after buying an additional 850 shares during the period. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $73.97 on Tuesday. The stock has a market capitalization of $6.73 billion, a PE ratio of -13.62 and a beta of 1.84. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The business's 50-day moving average is $60.81 and its 200 day moving average is $50.52.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to analysts' expectations of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.CRISPR Therapeutics's quarterly revenue was up 72.5% on a year-over-year basis. During the same period last year, the firm earned ($1.49) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on CRSP shares. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. Barclays lifted their price objective on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Chardan Capital reiterated a "buy" rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $72.59.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares of the company's stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,213 shares of company stock worth $3,810,458 over the last three months. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.